Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil

ABSTRACT Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder caused by a mutation in the SERPINA1 gene, which encodes the protease inhibitor alpha-1 antitrypsin (AAT). Severe AATD predisposes individuals to COPD and liver disease. Early diagnosis is essential for implementing preventive measures and limiting the disease burden. Although national and international guidelines for the diagnosis and management of AATD have been available for 20 years, more than 85% of cases go undiagnosed and therefore untreated. In Brazil, reasons for the underdiagnosis of AATD include a lack of awareness of the condition among physicians, a racially diverse population, serum AAT levels being assessed in a limited number of individuals, and lack of convenient diagnostic tools. The diagnosis of AATD is based on laboratory test results. The standard diagnostic approach involves the assessment of serum AAT levels, followed by phenotyping, genotyping, gene sequencing, or combinations of those, to detect the specific mutation. Over the past 10 years, new techniques have been developed, offering a rapid, minimally invasive, reliable alternative to traditional testing methods. One such test available in Brazil is the A1AT Genotyping Test, which simultaneously analyzes the 14 most prevalent AATD mutations, using DNA extracted from a buccal swab or dried blood spot. Such advances may contribute to overcoming the problem of underdiagnosis in Brazil and elsewhere, as well as being likely to increase the rate detection of AATD and therefore mitigate the harmful effects of delayed diagnosis.

Saved in:
Bibliographic Details
Main Authors: Jardim,José R, Casas-Maldonado,Francisco, Fernandes,Frederico Leon Arrabal, Castellano,Maria Vera Cruz de O, Torres-Durán,María, Miravitlles,Marc
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Pneumologia e Tisiologia 2021
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132021000300501
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1806-37132021000300501
record_format ojs
spelling oai:scielo:S1806-371320210003005012021-05-28Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in BrazilJardim,José RCasas-Maldonado,FranciscoFernandes,Frederico Leon ArrabalCastellano,Maria Vera Cruz de OTorres-Durán,MaríaMiravitlles,Marc alpha 1-antitrypsin deficiency/diagnosis alpha 1-antitrypsin deficiency/genetics Genotyping techniques ABSTRACT Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder caused by a mutation in the SERPINA1 gene, which encodes the protease inhibitor alpha-1 antitrypsin (AAT). Severe AATD predisposes individuals to COPD and liver disease. Early diagnosis is essential for implementing preventive measures and limiting the disease burden. Although national and international guidelines for the diagnosis and management of AATD have been available for 20 years, more than 85% of cases go undiagnosed and therefore untreated. In Brazil, reasons for the underdiagnosis of AATD include a lack of awareness of the condition among physicians, a racially diverse population, serum AAT levels being assessed in a limited number of individuals, and lack of convenient diagnostic tools. The diagnosis of AATD is based on laboratory test results. The standard diagnostic approach involves the assessment of serum AAT levels, followed by phenotyping, genotyping, gene sequencing, or combinations of those, to detect the specific mutation. Over the past 10 years, new techniques have been developed, offering a rapid, minimally invasive, reliable alternative to traditional testing methods. One such test available in Brazil is the A1AT Genotyping Test, which simultaneously analyzes the 14 most prevalent AATD mutations, using DNA extracted from a buccal swab or dried blood spot. Such advances may contribute to overcoming the problem of underdiagnosis in Brazil and elsewhere, as well as being likely to increase the rate detection of AATD and therefore mitigate the harmful effects of delayed diagnosis.info:eu-repo/semantics/openAccessSociedade Brasileira de Pneumologia e TisiologiaJornal Brasileiro de Pneumologia v.47 n.3 20212021-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132021000300501en10.36416/1806-3756/e20200380
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Jardim,José R
Casas-Maldonado,Francisco
Fernandes,Frederico Leon Arrabal
Castellano,Maria Vera Cruz de O
Torres-Durán,María
Miravitlles,Marc
spellingShingle Jardim,José R
Casas-Maldonado,Francisco
Fernandes,Frederico Leon Arrabal
Castellano,Maria Vera Cruz de O
Torres-Durán,María
Miravitlles,Marc
Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil
author_facet Jardim,José R
Casas-Maldonado,Francisco
Fernandes,Frederico Leon Arrabal
Castellano,Maria Vera Cruz de O
Torres-Durán,María
Miravitlles,Marc
author_sort Jardim,José R
title Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil
title_short Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil
title_full Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil
title_fullStr Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil
title_full_unstemmed Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil
title_sort update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in brazil
description ABSTRACT Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder caused by a mutation in the SERPINA1 gene, which encodes the protease inhibitor alpha-1 antitrypsin (AAT). Severe AATD predisposes individuals to COPD and liver disease. Early diagnosis is essential for implementing preventive measures and limiting the disease burden. Although national and international guidelines for the diagnosis and management of AATD have been available for 20 years, more than 85% of cases go undiagnosed and therefore untreated. In Brazil, reasons for the underdiagnosis of AATD include a lack of awareness of the condition among physicians, a racially diverse population, serum AAT levels being assessed in a limited number of individuals, and lack of convenient diagnostic tools. The diagnosis of AATD is based on laboratory test results. The standard diagnostic approach involves the assessment of serum AAT levels, followed by phenotyping, genotyping, gene sequencing, or combinations of those, to detect the specific mutation. Over the past 10 years, new techniques have been developed, offering a rapid, minimally invasive, reliable alternative to traditional testing methods. One such test available in Brazil is the A1AT Genotyping Test, which simultaneously analyzes the 14 most prevalent AATD mutations, using DNA extracted from a buccal swab or dried blood spot. Such advances may contribute to overcoming the problem of underdiagnosis in Brazil and elsewhere, as well as being likely to increase the rate detection of AATD and therefore mitigate the harmful effects of delayed diagnosis.
publisher Sociedade Brasileira de Pneumologia e Tisiologia
publishDate 2021
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132021000300501
work_keys_str_mv AT jardimjoser updateonandfutureperspectivesforthediagnosisofalpha1antitrypsindeficiencyinbrazil
AT casasmaldonadofrancisco updateonandfutureperspectivesforthediagnosisofalpha1antitrypsindeficiencyinbrazil
AT fernandesfredericoleonarrabal updateonandfutureperspectivesforthediagnosisofalpha1antitrypsindeficiencyinbrazil
AT castellanomariaveracruzdeo updateonandfutureperspectivesforthediagnosisofalpha1antitrypsindeficiencyinbrazil
AT torresduranmaria updateonandfutureperspectivesforthediagnosisofalpha1antitrypsindeficiencyinbrazil
AT miravitllesmarc updateonandfutureperspectivesforthediagnosisofalpha1antitrypsindeficiencyinbrazil
_version_ 1756431159712022528